Search
× Search

Baza informacij za delovanje Partnerjev Mreže Modro Poslovanje

0 0

CELEX:62016CJ0680_SUM: Judgment of the Court (Fourth Chamber) of 27 March 2019.#Dr. August Wolff GmbH & Co. KG Arzneimittel and Remedia d.o.o. v European Commission.#Appeal — Medicinal products for human use — Directive 2001/83/EC — Article 30(1) — Committee for Medicinal Products for Human Use — Referral of a matter to the committee subject to the absence of a previous national decision — Active substance estradiol — Decision of the European Commission ordering the Member States to revoke or vary marketing authorisations for medicinal products with 0.01% estradiol by weight for topical use.#Case C-680/16 P.

0 0

CELEX:62016TA0263: Cases T-263/16 RENV, T-265/16, T-311/16, T-319/16, T-321/16, T-343/16, T-350/16, T-444/16, T-800/16 and T-832/16: Judgment of the General Court of 20 September 2023 — Magnetrol International and Others v Commission (State aid — Aid scheme put into effect by Belgium — Decision declaring the aid scheme incompatible with the internal market and unlawful and ordering recovery of the aid granted — Tax ruling — Taxable profit — Excess profit exemption — Advantage — Selectivity — Recovery)

0 0

CELEX:62016TA0303: Case T-303/16: Judgment of the General Court of 26 January 2022 — Mylan IRE Healthcare v Commission (Medicinal products for human use — Orphan medicinal products — Marketing authorisations for the medicinal products Tobramycin VVB and associated names — Derogation from the market exclusivity of Tobi Podhaler, containing the active substance tobramycin — Article 8(3)(c) of Regulation (EC) No 141/2000 — Concept of ‘significant benefit’ — Concept of ‘clinical superiority’ — Article 3(2) and (3)(d) of Regulation (EC) No 847/2000 — Duty of care — Manifest error of assessment)

RSS
First592593594595597599600601Last

Poišči članke o davkih v bazi Modro poslovanje

Terms Of UsePrivacy StatementCopyright 2014-2014 by Srobotnik d.o.o.
Back To Top